James Chelnis, MD, FACS, is an ophthalmic plastic and reconstructive surgeon at Manhattan Face & Eye. At the 2025 American ...

Phase 3 Trial Design: The FDA agreed with Adagene’s proposed standard-of-care (SOC) control arm for the Phase 3 clinical trial and confirmed that a muzastotug monotherapy arm was also not required.

CHICAGO -- Plaque psoriasis drug deucravacitinib (Sotyktu) now looks likely to win a psoriatic arthritis (PsA) indication in ...

Rosnilimab acts as an agonist to stimulate PD-1, killing those cells with high PD-1 expression and pushing others into an ...

Q3 2025 Earnings Call Transcript October 29, 2025 Bausch Health Companies Inc. misses on earnings expectations. Reported EPS ...

MEMBERS of a growing environmental partnership have been given a “fascinating” insight into how a North East health trust is ...

Oral presentation name: Enobosarm in Combination With GLP-1RA is Selective for Fat Loss While Preserving Lean and Function ...

Cash and investments are sufficient to fund current operations through Q2 2027, not including VenoValve commercialization and ...

The presentation will provide two-year follow-up data from the landmark BOOSTB4 Phase I/II clinical study. Notably, the results demonstrate that more than 50% of the treated patients experienced zero ...

A subgroup analysis of patients with moderately to severely active Crohn’s disease showed greater clinical and endoscopic ...

Q3 2025 Earnings Call October 30, 2025 8:30 AM EDTCompany ParticipantsJon Cohen - CEO & DirectorIan Harris - Chief ...

AI’s true power lies in pattern recognition across messy, real-world data: Natural language processing extracts phenotypes, comorbidities, and device usability feedback from unstructured clinical ...